Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Vodicka, Prokop
6  Ergebnisse:
Personensuche X
?
1

Idelalisib plus rituximab versus ibrutinib in the treatment..:

Špaček, Martin ; Smolej, Lukáš ; Šimkovič, Martin...
British Journal of Haematology.  202 (2023)  1 - p. 40-47 , 2023
Link: https://doi.org/10.1111/..
 
?
2

Polatuzumab vedotin plus bendamustine and rituximab in pati..:

Vodicka, Prokop ; Benesova, Katerina ; Janikova, Andrea...
European Journal of Haematology.  109 (2022)  2 - p. 162-165 , 2022
Link: https://doi.org/10.1111/..
 
?
3

Diffuse Large B-Cell Lymphoma (DLBCL): Early Patient Manage..:

Vodicka, Prokop ; Klener, Pavel ; Trneny, Marek
OncoTargets and Therapy.  15 (2022)  - p. 1481-1501 , 2022
Link: https://doi.org/10.2147/..
 
?
4

Diffuse Large B-Cell Lymphoma (DLBCL): Early Patient Manage..:

Vodicka, Prokop ; Klener, Pavel ; Trneny, Marek
info:eu-repo/semantics/altIdentifier/doi/10.2147/OTT.S326632.  , 2022
Link: https://www.dovepress.co..
 
?
5

Diffuse Large B-Cell Lymphoma (DLBCL): Early Patient Manage..:

Vodicka, Prokop ; Klener, Pavel ; Trneny, Marek
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9739046/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
6

Expression of molecules of the Wnt pathway and of E-cadheri..:

Vodicka, Prokop ; Krskova, Lenka ; Odintsov, Igor...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7039126/.  , 2020
Link: http://www.ncbi.nlm.nih...
 
1-6